valsartan/amlodipine/chlorthalidone (AJU-C52L) / AJU Pharm - LARVOL DELTA

Efficacy and Safety of AJU-C52 in Essential Hypertension Patients (clinicaltrials.gov) - P3 | N=193 | Completed | Sponsor: AJU Pharm Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial. (PubMed, J Clin Hypertens (Greenwich)) - P3 | "Triple combination therapy with Val/Aml/CTD demonstrated superior blood pressure reduction and a favorable safety profile in patients with essential hypertension inadequately controlled on Val/Aml dual therapy, supporting its use as an effective treatment option in this population. Trial Registration: This trial was prospectively registered at ClinicalTrials.gov (identifier: NCT06416865)."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Cardiovascular • Hypertension

Efficacy and Safety Profile of a Triple Single-Pill Combination of Valsartan/Amlodipine/Chlorthalidone in Patients with Uncontrolled Hypertension. (PubMed, Clin Ther) - P3 | "This trial reported that the single-pill triple combination KDF1901 significantly improved BP control compared with dual therapy without compromising tolerability."

Clinical • Journal • Cardiovascular • Hypertension

High Stakes Under Low Androgens: Amiloride Conquers Abiraterone-Driven Resistant Hypertension (KIDNEY WEEK 2025) - "Case Description A 70-year-old man with metastatic PC, diabetes (metformin), no prior HTN, began ABI + prednisone. This patient's hypertension persisted despite amlodipine, valsartan, and chlorthalidone but fell to 125/83 mmHg once amiloride, a potassium-sparing blocker of distal sodium reabsorption that does not engage the AR, replaced MRA that might blunt ABI's anticancer activity. ACEi remain useful adjuncts, yet amiloride offers an androgen-neutral strategy for controlling rHTN during ABI therapy and warrants prospective study."

Cardiovascular • Diabetes • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Hypertension • Metabolic Disorders • Prostate Cancer • Solid Tumor • AR • CYP17A1

Efficacy and Safety of AJU-C52 in Essential Hypertension Patients (clinicaltrials.gov) - P3 | N=190 | Recruiting | Sponsor: AJU Pharm Co., Ltd.

New P3 trial • Cardiovascular • Hypertension